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Adeno-associated virus (AAV) is a defective mono-stranded
DNA virus, endemic in human population (35–80%). Recurrent
clonal AAV2 insertions are associated with the pathogenesis of
rare human hepatocellular carcinoma (HCC) developed on normal
liver. This study aimed to characterize the natural history of AAV
infection in the liver and its consequence in tumor development.
Viral DNA was quantified in tumor and non-tumor liver tissues of
1461 patients and in silico analyses using viral capture data ex-
plored viral variants and new clonal insertions. AAV DNA was
detected in 21% of the patients, more frequently in the non-tumor
counterpart (18%) than in tumor (8%). The full-length viral se-
quences were reconstructed in 57 patients leading to identify two
distinct AAV subtypes: one similar to AAV2, the other hybrid
betweenAAV2 andAAV13 sequences. Episomal viral formswere
found in 4% of the non-tumor tissues, frequently associated with
viral RNA expression and human herpesvirus type 6 (HHV6), the
candidate natural AAV helper virus. In 30 HCC, clonal AAV
insertions were recurrently identified in CCNA2, CCNE1, TERT,
TNFSF10, KMT2B and GLI1/INHBE. AAV insertion triggered
oncogenic overexpression through multiple mechanisms that dif-
fer according to the localization of the integration site. Clonal
AAV insertionswere positively selected duringHCC development
on non-cirrhotic liver challenging the notion of AAV as a non-
pathogenic virus. In conclusion, this is the first large scale study
that provides an integrated analysis of wild type AAV infection in
the liver with the identification of viral genotypes, molecular
forms, helper virus relationship and viral integrations.
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A fundamental goal of cancer drug delivery is to achieve suf-
ficient levels within the tumour without leading to high systemic
concentrations that might cause off-target toxicities. In situ pro-
duction of protein-based therapeutics by tumour cells provides an
attractive alternative to treatment with repeated high bolus in-
jections, as secretion by the tumour itself could provide high local
concentrations that act in a paracrine fashion over an extended
duration. For this purpose, we have developed a non-oncolytic
adenoviral delivery system that allows for targeting of Ad5 to
discrete cell types by redirecting viral tropism to cell surface
biomarkers through the use of interchangeable adapters. Fur-
thermore, we recently described the engineering of a protein-
based ‘shield’ that is coated on the Ad5 capsid, which, together
with the retargeting adapters, allows for improved tumour speci-
ficity and prevention of viral clearance. To test this delivery
strategy in vivo, SCID-beige mice bearing orthotopic BT474
xenografts were treated with three doses of either a cancer-
specific, non-replicative Ad5 that encodes a secreted anti-HER2
antibody, trastuzumab, in its genome, or with the protein thera-
peutic itself (Herceptin). We have employed state-of-the-art
whole tumour clearing and imaging with confocal microscopy at
high spatial resolution in 3D to assess biodistribution, and large
volumetric imaging has revealed that the secreted therapeutic
diffuses significantly throughout the tumour leading to a thera-
peutic effect and delayed tumour outgrowth. Moreover, the sys-
temic concentration of antibody is significantly reduced with viral
delivery, suggesting that paracrine delivery may be a promising
strategy for delivery of biologics with narrow therapeutic indices.
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